| First Author | Moore PC | Year | 2019 |
| Journal | Cancer Res | Volume | 79 |
| Issue | 24 | Pages | 6190-6203 |
| PubMed ID | 31672843 | Mgi Jnum | J:282670 |
| Mgi Id | MGI:6381477 | Doi | 10.1158/0008-5472.CAN-19-1116 |
| Citation | Moore PC, et al. (2019) Parallel Signaling through IRE1alpha and PERK Regulates Pancreatic Neuroendocrine Tumor Growth and Survival. Cancer Res 79(24):6190-6203 |
| abstractText | Master regulators of the unfolded protein response (UPR), IRE1alpha and PERK, promote adaptation or apoptosis depending on the level of endoplasmic reticulum (ER) stress. Although the UPR is activated in many cancers, its effects on tumor growth remain unclear. Derived from endocrine cells, pancreatic neuroendocrine tumors (PanNET) universally hypersecrete one or more peptide hormones, likely sensitizing these cells to high ER protein-folding stress. To assess whether targeting the UPR is a viable therapeutic strategy, we analyzed human PanNET samples and found evidence of elevated ER stress and UPR activation. Genetic and pharmacologic modulation of IRE1alpha and PERK in cultured cells, xenograft, and spontaneous genetic (RIP-Tag2) mouse models of PanNETs revealed that UPR signaling was optimized for adaptation and that inhibiting either IRE1alpha or PERK led to hyperactivation and apoptotic signaling through the reciprocal arm, thereby halting tumor growth and survival. These results provide a strong rationale for therapeutically targeting the UPR in PanNETs and other cancers with elevated ER stress. SIGNIFICANCE: The UPR is upregulated in pancreatic neuroendocrine tumors and its inhibition significantly reduces tumor growth in preclinical models, providing strong rationale for targeting the UPR in these cancers. |
